• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Editas Medicine (NQ: EDIT )

    2.910 +0.010 (+0.34%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Editas Medicine

    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Editas Medicine: Q2 Earnings Insights
      Editas Medicine (NASDAQ:EDIT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
    From Editas Medicine, Inc.
    Via GlobeNewswire
    BMO Initiates Coverage On This Gene Editing Spearhead
    Via Benzinga
    Expert Ratings for Editas Medicine
    Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter: 
    Via Benzinga
    The 3 Leaders of the Gene Editing Revolution
    There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
    Via InvestorPlace
    7 Moonshot Investments Upending a $10 Trillion Industry
    Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
    Via InvestorPlace
    The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Good morning! We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for Tuesday! 
    Via InvestorPlace
    Editas Medicine: Q1 Earnings Insights
    Editas Medicine (NASDAQ:EDIT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    16 Stocks Moving in Tuesday's Pre-Market Session
    Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares rose 38% to $1.27 in pre-market trading following a Form 4 filing showing the purchase of 2,044,676 shares by CEO Salvatore Palella at an average price of... 
    Via Benzinga
    Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.
    Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves? 
    Via InvestorPlace
    Editas Medicine's Return On Capital Employed Insights
    Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter. 
    Via Benzinga
    The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Editas Medicine Earnings Conference Call Is Coming Up, Here's What You Need To Know
    Editas Medicine (NASDAQ:EDIT) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Editas Medicine (EDIT) Conference Call Follow this link to... 
    Via Benzinga
    Editas Medicine's EDIT-301 receives FDA Rare Pediatric Disease designation for Beta Thalassemia
    The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia from leading... 
    Via Benzinga
    Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents
    The U.S. Patent and Trademark Office has ruled in favor of the Broad Institute of MIT and Harvard in a dispute over the patents around CRISPR gene-editing technology. The... 
    Via Benzinga
    The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
    Via Benzinga
    27 Stocks Moving in Monday's Pre-Market Session
    Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 123.4% to $0.76 in pre-market trading after jumping 36% on Monday. American Rebel Holdings, Inc. (NASDAQ: AREB) rose 28.6... 
    Via Benzinga
    Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
    Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein. 
    Via Investor's Business Daily
    Expert Ratings For Editas Medicine
    Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
    Via Benzinga
    The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
    Via Benzinga
    The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
    Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
    Via Benzinga
    Editas Suddenly Terminates Chief Medical Officer Without An Explanation
    Editas Medicine Inc (NASDAQ: EDIT) has fired Chief Medical Officer Lisa Michaels just 15 months into her tenure at the Company. 
    Via Benzinga
    51 Biggest Movers From Yesterday
    Also check out this: Apple And 3 Other Stocks Sold By Insiders Losers SelectQuote, Inc. (NYSE: SLQT) shares tumbled 47.3% to close at $3.44 on Tuesday after the company... 
    Via Benzinga
    35 Stocks Moving In Tuesday's Mid-Day Session
    Gainers Society Pass Incorporated (NASDAQ: SOPA) gained 63.4% to $3.45 after dropping 16% on Monday. American Rebel Holdings, Inc. (NASDAQ: AREB) climbed 56.1% to $3.45 following... 
    Via Benzinga
    The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Gainers Second Sight Medical (NASDAQ:EYES) stock increased by 7.8% to $1.51 during Tuesday's pre-market session. The market value of their outstanding shares is at $59... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Good morning! We've got another busy day ahead of us so let's get right into it with the biggest pre-market stock movers for Tuesday! 
    Via InvestorPlace
    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.